Gubra A/S (the "Company") completed a capital increase on 8 June 2026 as a result of the exercise of warrants granted in 2023.
In accordance with section 32 of the Danish Capital Markets Act, the Company is required to disclose the total number of voting rights and shares in the event of changes.
As of 30 June 2026, the number of shares, the number of voting rights, and the share capital are as shown below:
Number of shares: 16,435,575
Number of votes: 16,435,575
Share capital (DKK): 16,435,575.00
Contacts at Gubra
Media: Marianne Thomas (mho@gubra.dk, +45 2483 2663)
Investors: Kristian Borbos (kbo@gubra.dk, +45 3080 8035) and Adam Lange (adl@gubra.dk, +45 6646 1589)
About Gubra
Gubra, founded in 2008 in Denmark and listed on NASDAQ Copenhagen, is a disease-agnostic techbio company specialized in peptide-based drug discovery and preclinical contract research services. Gubra’s activities are focused on the early stages of drug development and are organized in three main business units – Biotech, CRO, and Ventures. The business areas create a unique entity capable of generating a steady cash flow from the CRO business while investing in high-impact biotech R&D projects with significant value inflection potential through partnerships. Gubra has around 300 employees and had revenue of DKK 2.6 billion (around $400 million) in 2025.
See www.gubra.dk for more information.